疗效是通过将非诺贝特加入辛伐他汀里取得的。
目的：合成降脂药辛伐他汀。
目的探讨辛伐他汀滴丸的体外溶出速率。
OBJECTIVE To study the dissolution rate in vitro of simvastatin pills.
目的比较不同剂量辛伐他汀降血脂效果。
Aim To compare the effects of different doses of simvastatin on decreasing blood-lipoids.
这些限制适用于所有使用辛伐他汀的患者。
目的探讨辛伐他汀对关节软骨的保护作用。
Objective To examine the protective effects of simvastatin on articular cartilage in vitro.
目的了解辛伐他汀的副作用，提倡合理用药。
Objective: To understand the adverse effects of simvastatin and promote rational medication.
目的制备辛伐他汀缓释滴丸并优化其制备工艺。
OBJECTIVE To prepare sustained-release dropping pills of Simvastatin and optimize its preparation technology.
前言：目的：探讨影响辛伐他汀降脂疗效的临床因素。
Objective: To study the effects on lipid - lowing therapy of simvastatin.
目的探讨辛伐他汀联合非诺贝特治疗混合性高脂血症的价值。
Objective To discuss the val ue of simvastatin plus fenofibrate for the treatment of mixed hyperlipemia.
目的研究辛伐他汀治疗高脂血症对骨形成生化标志物的影响。
OBJECTIVE To investigate the effect of simvastatin on biochemical markers of bone formation in treating the patients with hyperlipidemia.
作为单一成分出售的辛伐他汀是非专利药，商品名为舒降之。
Simvastatin is sold as a single-ingredient generic medication and as the brand-name Zocor.
结论：辛伐他汀降血脂同时具有降蛋白尿和保护肾功能作用。
CONCLUSION: Simvastatin can decrease lipidemia, associated to the proteinuria decrease and the protection of renal function.
SEARCH同时包括患者服用辛伐他汀出现肌肉损伤的数据。
SEARCH also included data on muscle injury in patients taking simvastatin.
辛伐他汀和胞二磷胆碱可减轻新生大鼠hibd后脑组织损害。
Both simvastatin and CDPC can relieve the damages of the brain in rats HIBD.
槟榔碱、PPVP、DMHPPP和辛伐他汀可以减轻其过量表达。
The over expression could be blocked by arecoline, PPVP, DMHPPP and simvastatin.
辛伐他汀治疗后肱动脉内径和肱动脉对硝酸甘油的反应均无显著改变。
There was no significant change of vasodilation responding to nitroglycerin and brachial diameter in all groups after simvastatin therapy.
目的探讨辛伐他汀对颈动脉内膜-中膜厚度及颈动脉粥样硬化斑块的影响。
Objective To investigate the influences of simvastatin on carotid artery Intima-media thickness (IMT) and carotid atherosclerotic plaque.
目的观察辛伐他汀对高肺血流并野百合碱注射大鼠肺动脉高压模型的影响。
Objective To explore the therapeutic effect of simvastatin on the pulmonary hypertension induced by injected monocrotaline combining with high pulmonary blood flow of rats.
当辛伐他汀（特别是大剂量）与某些药物联合服用时，也会增加肌病的风险。
The risk of myopathy is also increased when simvastatin, especially at the higher doses, is used with certain drugs (see Simvastatin Dose Limitations below).
目的：探索辛伐他汀对糖尿病肾病高脂血症降血脂疗效和保护肾功能的作用。
AIM: To probe the efficacy of simvastatin for lowering lipidemia in diabetic nephropathy with hyperlipidemia and protecting renal function.
目的：探讨早期应用辛伐他汀对急性冠脉综合征患者的血脂和C反应蛋白影响。
Objective To observe the influence of simvastatin on blood lipid and Creactive protein in patients with acute coronary syndrome.
结论辛伐他汀可以降低糖尿病大鼠肾肥大指数，对糖尿病肾脏病变有保护作用。
Conclusion Simvastatin can reduce the kidney hypertrophy index in the diabetic rats and it has renal protective effect on the diabetic rats.
结论辛伐他汀治疗16周可以通过降低血管阻力增加血流量改善脑血管供血状态。
Conclusions Simvastatin, after 16 weeks of treatment, can be lower vascular obstruction, increase blood flow, and thus improve brain blood supply.
结论辛伐他汀低剂量维持治疗，患者耐受性好，疗效确切，能保持血脂水平持续达标。
Conclusions Patients have a good tolerance, good effects and can keep continuous qualified serum lipid level after maintaining treatment with low dosage of simvastatin.
结论：辛伐他汀促进骨髓基质细胞的分化，提高其矿化能力，有助于骨质疏松症的防治。
Conclusion: We confirmed that simvastatin promote differentiation and capacity of mineralization of BMSC and contribute to the prevention and treatment of osteoporosis.
目的：研究辛伐他汀对大鼠成骨细胞增殖和分化功能的影响，探讨其刺激成骨的作用机制。
Objective: to study the effect of simvastatin on osteoblast proliferation and differentiation and to explore the mechanism of stimulation of bone formation by simvastatin.
目的探讨不同剂量辛伐他汀治疗急性心肌梗死合并阵发性心房颤动心脏复律后的近期疗效。
Objectives To investigate the effects of different dosage of simvastatin on acute myocardial infarction with paroxysmal atrial fibrillation.
但是，辛伐他汀及其主要代谢产物辛伐他汀酸的药代动力学参数没有出现统计学上的差异。
However, no significant discrepancy was detected in the pharmacokinetics parameters of simvastatin and its main metabolite simvastatin aicd.
但是，辛伐他汀及其主要代谢产物辛伐他汀酸的药代动力学参数没有出现统计学上的差异。
However, no significant discrepancy was detected in the pharmacokinetics parameters of simvastatin and its main metabolite simvastatin aicd.
应用推荐